Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Frequent amyloid deposition without significant cognitive impairment among the elderly.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE.

Arch Neurol. 2008 Nov;65(11):1509-17. doi: 10.1001/archneur.65.11.1509.

2.

Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E ε4 Genotype.

Nadkarni NK, Perera S, Snitz BE, Mathis CA, Price J, Williamson JD, DeKosky ST, Klunk WE, Lopez OL.

JAMA Neurol. 2017 Jan 1;74(1):82-90. doi: 10.1001/jamaneurol.2016.3474.

3.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

PMID:
22628162
4.

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA.

J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47.

PMID:
15944649
5.

The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction.

Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, DeCarli C, Weiner MW, Mungas DM, Chui HC, Jagust WJ.

JAMA Neurol. 2013 Apr;70(4):488-95. doi: 10.1001/2013.jamaneurol.405.

6.

Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.

Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ.

Arch Neurol. 2012 Feb;69(2):223-9. doi: 10.1001/archneurol.2011.666.

7.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

8.

Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.

Hatashita S, Yamasaki H.

J Alzheimers Dis. 2010;21(3):995-1003. doi: 10.3233/JAD-2010-100222.

PMID:
20693641
9.

Fibrillar amyloid correlates of preclinical cognitive decline.

Stonnington CM, Chen K, Lee W, Locke DE, Dueck AC, Liu X, Roontiva A, Fleisher AS, Caselli RJ, Reiman EM.

Alzheimers Dement. 2014 Jan;10(1):e1-8. doi: 10.1016/j.jalz.2013.01.009. Epub 2013 Apr 11.

10.

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.

Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH.

Neurology. 2013 Jan 1;80(1):85-91. doi: 10.1212/WNL.0b013e31827b1a07. Epub 2012 Dec 12.

11.

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC.

Ann Neurol. 2011 Jan;69(1):181-92. doi: 10.1002/ana.22248.

12.

Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.

McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, Ziolko S, Berginc M, Lopresti B, Dekosky S, Mathis CA.

J Nucl Med. 2009 Mar;50(3):348-55. doi: 10.2967/jnumed.108.057612. Epub 2009 Feb 17.

13.

Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels.

Choi HJ, Seo EH, Yi D, Sohn BK, Choe YM, Byun MS, Lee JM, Woo JI, Lee DY.

Am J Geriatr Psychiatry. 2016 Feb;24(2):144-53. doi: 10.1016/j.jagp.2015.06.004. Epub 2015 Jun 26.

PMID:
26238231
14.

The evaluation of brain perfusion SPECT using an easy Z-score imaging system in the mild cognitive impairment subjects with brain amyloid-β deposition.

Takemaru M, Kimura N, Abe Y, Goto M, Matsubara E.

Clin Neurol Neurosurg. 2017 Sep;160:111-115. doi: 10.1016/j.clineuro.2017.06.018. Epub 2017 Jul 5.

PMID:
28715708
15.

Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults.

Snitz BE, Weissfeld LA, Cohen AD, Lopez OL, Nebes RD, Aizenstein HJ, McDade E, Price JC, Mathis CA, Klunk WE.

Am J Geriatr Psychiatry. 2015 Sep;23(9):985-93. doi: 10.1016/j.jagp.2015.01.008. Epub 2015 Feb 11.

16.

In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, Rosario BL, Lopresti BJ, Saxton JA, Aizenstein HJ, McDade EM, Kamboh MI, DeKosky ST, Lopez OL.

Ann Neurol. 2013 Jun;73(6):751-61. doi: 10.1002/ana.23797. Epub 2013 Apr 17.

17.

Imaging amyloid deposition in Lewy body diseases.

Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA.

Neurology. 2008 Sep 16;71(12):903-10. doi: 10.1212/01.wnl.0000326146.60732.d6.

18.

Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.

Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T, Holtzman DM, Morris JC.

Arch Neurol. 2012 May;69(5):636-43.

19.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.

PMID:
16854944
20.

Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia.

Petrou M, Bohnen NI, Müller ML, Koeppe RA, Albin RL, Frey KA.

Neurology. 2012 Sep 11;79(11):1161-7. doi: 10.1212/WNL.0b013e3182698d4a. Epub 2012 Aug 29.

Supplemental Content

Support Center